Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
BOTHELL, Wash., May 10, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2017 Health Care Conference at 10:40 a.m. PT (1:40 p.m. ET) on Wednesday, May 17, 2017 in Las Vegas, NV. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
Link: http://www.veracast.com/webcasts/baml/healthcare2017/id46205172515.cfm
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contact: David Schull Russo Partners, LLC (212) 845-4271 [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected]
